Opinion|Videos|May 19, 2025
The current treatment landscape of mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Explore the latest advancements in metastatic hormone-sensitive prostate cancer treatment, highlighting effective agents and clinical trial outcomes.
Advertisement
Episodes in this series
Treatment Options for mHSPC
Key Themes:
- Current 2025 guidelines recommend ADT with intensification.
- Multiple intensification options include abiraterone, darolutamide, and docetaxel.
- Key clinical trials include ARANOTE, ARASENS, and TITAN.
- All studies demonstrate survival benefit and delayed disease progression with intensification.
Key Points for Physicians:
- ADT monotherapy is no longer the standard of care.
- Multiple evidence-based intensification options exist.
- Selection can be tailored based on patient characteristics and preferences.
- All intensification approaches demonstrate benefit over ADT alone.
Notable Insights: The evolution to combination therapy approaches represents a significant paradigm shift in the management of mHSPC, with multiple effective options now available.
Clinical Significance: The established benefit of intensification therapy has fundamentally changed the treatment landscape for mHSPC, providing multiple evidence-based approaches to improve outcomes.
Advertisement
Related to this article
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5